1. Home
  2. CVM vs TVGN Comparison

CVM vs TVGN Comparison

Compare CVM & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cel-Sci Corporation

CVM

Cel-Sci Corporation

SELL

Current Price

$1.57

Market Cap

24.1M

Sector

Health Care

ML Signal

SELL

Logo Tevogen Bio Holdings Inc.

TVGN

Tevogen Bio Holdings Inc.

N/A

Current Price

$5.60

Market Cap

21.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CVM
TVGN
Founded
1983
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
24.1M
21.3M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
CVM
TVGN
Price
$1.57
$5.60
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $12.50
N/A
AVG Volume (30 Days)
★ 101.5K
8.0K
Earning Date
11-27-2026
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $264,033.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 65.45
N/A
52 Week Low
$0.89
$0.14
52 Week High
$7.80
$24.91

Technical Indicators

Market Signals
Indicator
CVM
TVGN
Relative Strength Index (RSI) 53.11 48.17
Support Level $1.01 $5.01
Resistance Level $1.80 $7.55
Average True Range (ATR) 0.16 0.48
MACD 0.01 0.03
Stochastic Oscillator 73.54 51.00

Price Performance

Historical Comparison
CVM
TVGN

About CVM Cel-Sci Corporation

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

About TVGN Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.

Share on Social Networks: